Co-transplantation of mesenchymal stromal cell and haploidentical hematopoietic stem cell with TCR αβ depletion in children with primary immunodeficiency syndromes.
Didem AtayArzu AkcayBurcu AkıncıFatma Demir YenigürbüzErcument OvaliGulyuz OzturkPublished in: Pediatric transplantation (2021)
We conclude that use of TCR αβ depleted haploidentical transplantation with MSCs may ensure a rapid engraftment rate, low incidence of significant acute and chronic GVHD, and acceptable post-transplantation morbidity, especially in patients diagnosed with SCID and may be considered in children with PIDs. In younger patients (≤6 months), survival is comparable between HLA-matched graft and CD3+ TCRαβ depleted HLA-mismatched graft recipients.
Keyphrases
- end stage renal disease
- bone marrow
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cell therapy
- hematopoietic stem cell
- prognostic factors
- stem cells
- stem cell transplantation
- peripheral blood
- patient reported outcomes
- single cell
- risk factors
- liver failure
- low dose
- hepatitis b virus
- cord blood
- respiratory failure